Catenulopyrizomicins, new anti-Hepatitis B virus compounds, from the rare actinomycete Catenuloplanes sp. MM782L-181F7
Hepatitis B virus (HBV) causes chronic hepatitis in humans, and current antiviral therapies rarely treat viral infections. To improve the treatment efficacy, novel therapeutic agents, especially those with different mechanisms of action, need to be developed for use in combination with the current a...
Gespeichert in:
| Veröffentlicht in: | Journal of antibiotics 2024-02, Vol.77 (2), p.85-92 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 92 |
|---|---|
| container_issue | 2 |
| container_start_page | 85 |
| container_title | Journal of antibiotics |
| container_volume | 77 |
| creator | Yamasaki, Manabu Sawa, Ryuichi Muramatsu, Hideyuki Yamamoto, Yui Umekita, Maya Kubota, Yumiko Kanegae, Yumi Igarashi, Masayuki |
| description | Hepatitis B virus (HBV) causes chronic hepatitis in humans, and current antiviral therapies rarely treat viral infections. To improve the treatment efficacy, novel therapeutic agents, especially those with different mechanisms of action, need to be developed for use in combination with the current antivirals. Here, we isolated new anti-HBV compounds, named catenulopyrizomicins A–C, from the fermentation broth of rare actinomycete
Catenuloplanes
sp. MM782L-181F7. Structural analysis revealed that these compounds contained a structure that is composed of thiazolyl pyridine moiety. The catenulopyrizomicins reduced the amount of intracellular viral DNA in HepG2.2.15 cells with EC
50
values ranging from 1.94 to 2.63 µM with small but notable selectivity. Mechanistic studies indicated that catenulopyrizomicin promotes the release of immature virion particles that fail to be enveloped through alterations in membrane permeability. |
| doi_str_mv | 10.1038/s41429-023-00681-4 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2894360396</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2919209107</sourcerecordid><originalsourceid>FETCH-LOGICAL-c326t-eaa686560b534e6c1e719d927f9a9e0abe58194c218012f09042371b8b9587fa3</originalsourceid><addsrcrecordid>eNp9kU1vFDEMhiMEotvCH-CAInHh0BTnY_NxhBWlSFtxgXOUmfVAqp1kSGaKll9PypYiceBkS3782tJDyAsOFxykfVMVV8IxEJIBaMuZekRW3LaGK-0ekxWA4MxaASfktNYbAGmksU_JibQA1ki7IrebMGNa9nk6lPgzj7GPqZ7ThD9oSHNkVziFOc6x0nf0Npal0j6PU17SrlFDySOdvyEtoSAN_RxTHg89zkgfYvchYaV1uqDX18aKLeOWX5pn5MkQ9hWf39cz8uXy_efNFdt--vBx83bLein0zDAEbfVaQ7eWCnXP0XC3c8IMLjiE0OHacqd6wS1wMYADJaThne3c2pohyDPy-pg7lfx9wTr7MdYe93df5aV6YZ2SGqTTDX31D3qTl5Lad1447gQ4DqZR4kj1JddacPBTiWMoB8_B31nxRyu-WfG_rXjVll7eRy_diLuHlT8aGiCPQG2j9BXL39v_if0FeruWXA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2919209107</pqid></control><display><type>article</type><title>Catenulopyrizomicins, new anti-Hepatitis B virus compounds, from the rare actinomycete Catenuloplanes sp. MM782L-181F7</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Yamasaki, Manabu ; Sawa, Ryuichi ; Muramatsu, Hideyuki ; Yamamoto, Yui ; Umekita, Maya ; Kubota, Yumiko ; Kanegae, Yumi ; Igarashi, Masayuki</creator><creatorcontrib>Yamasaki, Manabu ; Sawa, Ryuichi ; Muramatsu, Hideyuki ; Yamamoto, Yui ; Umekita, Maya ; Kubota, Yumiko ; Kanegae, Yumi ; Igarashi, Masayuki</creatorcontrib><description>Hepatitis B virus (HBV) causes chronic hepatitis in humans, and current antiviral therapies rarely treat viral infections. To improve the treatment efficacy, novel therapeutic agents, especially those with different mechanisms of action, need to be developed for use in combination with the current antivirals. Here, we isolated new anti-HBV compounds, named catenulopyrizomicins A–C, from the fermentation broth of rare actinomycete
Catenuloplanes
sp. MM782L-181F7. Structural analysis revealed that these compounds contained a structure that is composed of thiazolyl pyridine moiety. The catenulopyrizomicins reduced the amount of intracellular viral DNA in HepG2.2.15 cells with EC
50
values ranging from 1.94 to 2.63 µM with small but notable selectivity. Mechanistic studies indicated that catenulopyrizomicin promotes the release of immature virion particles that fail to be enveloped through alterations in membrane permeability.</description><identifier>ISSN: 0021-8820</identifier><identifier>EISSN: 1881-1469</identifier><identifier>DOI: 10.1038/s41429-023-00681-4</identifier><identifier>PMID: 38008738</identifier><language>eng</language><publisher>Tokyo: Springer Japan</publisher><subject>13/44 ; 38/47 ; 38/77 ; 631/154 ; 631/154/1435 ; Actinobacteria - genetics ; Antibiotics ; Antiviral agents ; Antiviral Agents - pharmacology ; Bacteriology ; Biomedical and Life Sciences ; Bioorganic Chemistry ; Chromatography ; DNA methylation ; DNA, Viral - genetics ; DNA, Viral - pharmacology ; Fermentation ; Genomes ; Hep G2 Cells ; Hepatitis ; Hepatitis B ; Hepatitis B virus ; Humans ; Infections ; Life Sciences ; Medicinal Chemistry ; Membrane permeability ; Microbiology ; Natural products ; Organic Chemistry ; Pharmacology ; Structural analysis ; Viral infections ; Virions ; Virus Replication</subject><ispartof>Journal of antibiotics, 2024-02, Vol.77 (2), p.85-92</ispartof><rights>The Author(s), under exclusive licence to the Japan Antibiotics Research Association 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><rights>2023. The Author(s), under exclusive licence to the Japan Antibiotics Research Association.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c326t-eaa686560b534e6c1e719d927f9a9e0abe58194c218012f09042371b8b9587fa3</cites><orcidid>0000-0001-6698-5701 ; 0000-0002-1562-6685 ; 0000-0002-8190-0195 ; 0000-0001-5900-2113</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38008738$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yamasaki, Manabu</creatorcontrib><creatorcontrib>Sawa, Ryuichi</creatorcontrib><creatorcontrib>Muramatsu, Hideyuki</creatorcontrib><creatorcontrib>Yamamoto, Yui</creatorcontrib><creatorcontrib>Umekita, Maya</creatorcontrib><creatorcontrib>Kubota, Yumiko</creatorcontrib><creatorcontrib>Kanegae, Yumi</creatorcontrib><creatorcontrib>Igarashi, Masayuki</creatorcontrib><title>Catenulopyrizomicins, new anti-Hepatitis B virus compounds, from the rare actinomycete Catenuloplanes sp. MM782L-181F7</title><title>Journal of antibiotics</title><addtitle>J Antibiot</addtitle><addtitle>J Antibiot (Tokyo)</addtitle><description>Hepatitis B virus (HBV) causes chronic hepatitis in humans, and current antiviral therapies rarely treat viral infections. To improve the treatment efficacy, novel therapeutic agents, especially those with different mechanisms of action, need to be developed for use in combination with the current antivirals. Here, we isolated new anti-HBV compounds, named catenulopyrizomicins A–C, from the fermentation broth of rare actinomycete
Catenuloplanes
sp. MM782L-181F7. Structural analysis revealed that these compounds contained a structure that is composed of thiazolyl pyridine moiety. The catenulopyrizomicins reduced the amount of intracellular viral DNA in HepG2.2.15 cells with EC
50
values ranging from 1.94 to 2.63 µM with small but notable selectivity. Mechanistic studies indicated that catenulopyrizomicin promotes the release of immature virion particles that fail to be enveloped through alterations in membrane permeability.</description><subject>13/44</subject><subject>38/47</subject><subject>38/77</subject><subject>631/154</subject><subject>631/154/1435</subject><subject>Actinobacteria - genetics</subject><subject>Antibiotics</subject><subject>Antiviral agents</subject><subject>Antiviral Agents - pharmacology</subject><subject>Bacteriology</subject><subject>Biomedical and Life Sciences</subject><subject>Bioorganic Chemistry</subject><subject>Chromatography</subject><subject>DNA methylation</subject><subject>DNA, Viral - genetics</subject><subject>DNA, Viral - pharmacology</subject><subject>Fermentation</subject><subject>Genomes</subject><subject>Hep G2 Cells</subject><subject>Hepatitis</subject><subject>Hepatitis B</subject><subject>Hepatitis B virus</subject><subject>Humans</subject><subject>Infections</subject><subject>Life Sciences</subject><subject>Medicinal Chemistry</subject><subject>Membrane permeability</subject><subject>Microbiology</subject><subject>Natural products</subject><subject>Organic Chemistry</subject><subject>Pharmacology</subject><subject>Structural analysis</subject><subject>Viral infections</subject><subject>Virions</subject><subject>Virus Replication</subject><issn>0021-8820</issn><issn>1881-1469</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp9kU1vFDEMhiMEotvCH-CAInHh0BTnY_NxhBWlSFtxgXOUmfVAqp1kSGaKll9PypYiceBkS3782tJDyAsOFxykfVMVV8IxEJIBaMuZekRW3LaGK-0ekxWA4MxaASfktNYbAGmksU_JibQA1ki7IrebMGNa9nk6lPgzj7GPqZ7ThD9oSHNkVziFOc6x0nf0Npal0j6PU17SrlFDySOdvyEtoSAN_RxTHg89zkgfYvchYaV1uqDX18aKLeOWX5pn5MkQ9hWf39cz8uXy_efNFdt--vBx83bLein0zDAEbfVaQ7eWCnXP0XC3c8IMLjiE0OHacqd6wS1wMYADJaThne3c2pohyDPy-pg7lfx9wTr7MdYe93df5aV6YZ2SGqTTDX31D3qTl5Lad1447gQ4DqZR4kj1JddacPBTiWMoB8_B31nxRyu-WfG_rXjVll7eRy_diLuHlT8aGiCPQG2j9BXL39v_if0FeruWXA</recordid><startdate>20240201</startdate><enddate>20240201</enddate><creator>Yamasaki, Manabu</creator><creator>Sawa, Ryuichi</creator><creator>Muramatsu, Hideyuki</creator><creator>Yamamoto, Yui</creator><creator>Umekita, Maya</creator><creator>Kubota, Yumiko</creator><creator>Kanegae, Yumi</creator><creator>Igarashi, Masayuki</creator><general>Springer Japan</general><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-6698-5701</orcidid><orcidid>https://orcid.org/0000-0002-1562-6685</orcidid><orcidid>https://orcid.org/0000-0002-8190-0195</orcidid><orcidid>https://orcid.org/0000-0001-5900-2113</orcidid></search><sort><creationdate>20240201</creationdate><title>Catenulopyrizomicins, new anti-Hepatitis B virus compounds, from the rare actinomycete Catenuloplanes sp. MM782L-181F7</title><author>Yamasaki, Manabu ; Sawa, Ryuichi ; Muramatsu, Hideyuki ; Yamamoto, Yui ; Umekita, Maya ; Kubota, Yumiko ; Kanegae, Yumi ; Igarashi, Masayuki</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c326t-eaa686560b534e6c1e719d927f9a9e0abe58194c218012f09042371b8b9587fa3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>13/44</topic><topic>38/47</topic><topic>38/77</topic><topic>631/154</topic><topic>631/154/1435</topic><topic>Actinobacteria - genetics</topic><topic>Antibiotics</topic><topic>Antiviral agents</topic><topic>Antiviral Agents - pharmacology</topic><topic>Bacteriology</topic><topic>Biomedical and Life Sciences</topic><topic>Bioorganic Chemistry</topic><topic>Chromatography</topic><topic>DNA methylation</topic><topic>DNA, Viral - genetics</topic><topic>DNA, Viral - pharmacology</topic><topic>Fermentation</topic><topic>Genomes</topic><topic>Hep G2 Cells</topic><topic>Hepatitis</topic><topic>Hepatitis B</topic><topic>Hepatitis B virus</topic><topic>Humans</topic><topic>Infections</topic><topic>Life Sciences</topic><topic>Medicinal Chemistry</topic><topic>Membrane permeability</topic><topic>Microbiology</topic><topic>Natural products</topic><topic>Organic Chemistry</topic><topic>Pharmacology</topic><topic>Structural analysis</topic><topic>Viral infections</topic><topic>Virions</topic><topic>Virus Replication</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yamasaki, Manabu</creatorcontrib><creatorcontrib>Sawa, Ryuichi</creatorcontrib><creatorcontrib>Muramatsu, Hideyuki</creatorcontrib><creatorcontrib>Yamamoto, Yui</creatorcontrib><creatorcontrib>Umekita, Maya</creatorcontrib><creatorcontrib>Kubota, Yumiko</creatorcontrib><creatorcontrib>Kanegae, Yumi</creatorcontrib><creatorcontrib>Igarashi, Masayuki</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Immunology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection (ProQuest)</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of antibiotics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yamasaki, Manabu</au><au>Sawa, Ryuichi</au><au>Muramatsu, Hideyuki</au><au>Yamamoto, Yui</au><au>Umekita, Maya</au><au>Kubota, Yumiko</au><au>Kanegae, Yumi</au><au>Igarashi, Masayuki</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Catenulopyrizomicins, new anti-Hepatitis B virus compounds, from the rare actinomycete Catenuloplanes sp. MM782L-181F7</atitle><jtitle>Journal of antibiotics</jtitle><stitle>J Antibiot</stitle><addtitle>J Antibiot (Tokyo)</addtitle><date>2024-02-01</date><risdate>2024</risdate><volume>77</volume><issue>2</issue><spage>85</spage><epage>92</epage><pages>85-92</pages><issn>0021-8820</issn><eissn>1881-1469</eissn><abstract>Hepatitis B virus (HBV) causes chronic hepatitis in humans, and current antiviral therapies rarely treat viral infections. To improve the treatment efficacy, novel therapeutic agents, especially those with different mechanisms of action, need to be developed for use in combination with the current antivirals. Here, we isolated new anti-HBV compounds, named catenulopyrizomicins A–C, from the fermentation broth of rare actinomycete
Catenuloplanes
sp. MM782L-181F7. Structural analysis revealed that these compounds contained a structure that is composed of thiazolyl pyridine moiety. The catenulopyrizomicins reduced the amount of intracellular viral DNA in HepG2.2.15 cells with EC
50
values ranging from 1.94 to 2.63 µM with small but notable selectivity. Mechanistic studies indicated that catenulopyrizomicin promotes the release of immature virion particles that fail to be enveloped through alterations in membrane permeability.</abstract><cop>Tokyo</cop><pub>Springer Japan</pub><pmid>38008738</pmid><doi>10.1038/s41429-023-00681-4</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0001-6698-5701</orcidid><orcidid>https://orcid.org/0000-0002-1562-6685</orcidid><orcidid>https://orcid.org/0000-0002-8190-0195</orcidid><orcidid>https://orcid.org/0000-0001-5900-2113</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0021-8820 |
| ispartof | Journal of antibiotics, 2024-02, Vol.77 (2), p.85-92 |
| issn | 0021-8820 1881-1469 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2894360396 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | 13/44 38/47 38/77 631/154 631/154/1435 Actinobacteria - genetics Antibiotics Antiviral agents Antiviral Agents - pharmacology Bacteriology Biomedical and Life Sciences Bioorganic Chemistry Chromatography DNA methylation DNA, Viral - genetics DNA, Viral - pharmacology Fermentation Genomes Hep G2 Cells Hepatitis Hepatitis B Hepatitis B virus Humans Infections Life Sciences Medicinal Chemistry Membrane permeability Microbiology Natural products Organic Chemistry Pharmacology Structural analysis Viral infections Virions Virus Replication |
| title | Catenulopyrizomicins, new anti-Hepatitis B virus compounds, from the rare actinomycete Catenuloplanes sp. MM782L-181F7 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T21%3A08%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Catenulopyrizomicins,%20new%20anti-Hepatitis%20B%20virus%20compounds,%20from%20the%20rare%20actinomycete%20Catenuloplanes%20sp.%20MM782L-181F7&rft.jtitle=Journal%20of%20antibiotics&rft.au=Yamasaki,%20Manabu&rft.date=2024-02-01&rft.volume=77&rft.issue=2&rft.spage=85&rft.epage=92&rft.pages=85-92&rft.issn=0021-8820&rft.eissn=1881-1469&rft_id=info:doi/10.1038/s41429-023-00681-4&rft_dat=%3Cproquest_cross%3E2919209107%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2919209107&rft_id=info:pmid/38008738&rfr_iscdi=true |